Coronavirus Notebook: UK Tests Preventative Treatments As Row Escalates With EU Over Vaccine Supply
The procurement and authorization of vaccines are under scrutiny in the European Parliament this week. In the meantime, another Sputnik V spat is taking wing between Russia and the EU, while France has resumed the use of AstraZeneca’s vaccine, but only in the over-55s.
You may also be interested in...
Members of the European Parliament heard from top EU officials on initiatives being undertaken to strengthen the provision of coronavirus vaccines as member states try to deal with a surge in COVID-19 cases.
While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.
The US FDA will now have the full efficacy data that it wanted from AstraZeneca, but the company still has to deal with concerns over safety and global supply issues.